Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist: Attenuation of Endothelin-1–Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-κB

Open access
Dschietzig, Thomas, Bartsch, Cornelia, Richter, Christoph, Laule, Michael, Baumann, Gert, Stangl, Karl·2003·Circulation Research

Abstract

We have recently demonstrated that relaxin (RLX) acts as compensatory mediator in human heart failure. RLX inhibits the stimulation of endothelin-1, the most potent vasoconstrictor in heart failure. Upregulation of the endothelin type-B receptor (ET B ), which mediates endothelin-1 clearance and endothelial release of NO, represents a pivotal mode of RLX action. However, signal transduction and abundance of this phenomenon are unknown. Therefore, we investigated RLX-induced regulation of ET B in human umbilical vein endothelial, epithelial (HeLa), and vascular smooth muscle cells. In human umbilical vein endothelial cells and HeLa cells, but not in human vascular smooth muscle cells, RLX upregulated ET B expression and activated extracellular signal–regulated kinase-1/2 (ERK-1/2) and nuclear factor-κB (NF-κB), a transcription factor. PD-98059, a selective inhibitor of the mitogen-activated protein kinase kinase-1 (MEK-1)–ERK-1/2 pathway, abolished ERK-1/2 and NF-κB activation and ET B upregulation. NF-κB inhibition also prevented RLX-mediated ET B stimulation. In NF-κB-luciferase reporter assays, we demonstrated complete inhibition of RLX-induced NF-κB activation in cells transfected with dominant-negative Raf-1, MEK-1, or ERK-1/2 constructs, whereas dominant-negative Ras had no effect. In rat aorta and mesenteric artery, RLX pretreatment, in an ET B -dependent fashion, mitigated the maximum contractile response to endothelin-1, by 38±4% and 43±6%, and the endothelin-1 sensitivity (−log[EC 50 ]: aorta, 8.2±0.2 for vehicle versus 7.2±0.2 for RLX; mesenteric artery, 8.0±0.2 for vehicle versus 7.1±0.1 for RLX). RLX pretreatment augmented the dilator effect of the ET B agonist endothelin-3 by 100±8% and 133±13%. In conclusion, RLX stimulates endothelial and epithelial ET B via a Ras-independent Raf-1–MEK-1–ERK-1/2 pathway that activates NF-κB. On vascular smooth muscle cells, ET B , a contributor to endothelin-mediated vasoconstriction, remains unaffected. This renders RLX a functional endothelin-1 antagonist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.res.0000051884.27117.7e

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Dschietzig, T., Bartsch, C., Richter, C., Laule, M., Baumann, G., & Stangl, K.
Venue
Circulation Research
Published
2003-01-10
Volume
92
Issue
1
Pages
32-40
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
OpenAlex
W2116293808
Cited by
169
References
0
FWCI
5.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist: Attenuation of Endothelin-1–Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-κB. https://app.cochat.ai/papers/10.1161/01.res.0000051884.27117.7e
The paper
Dschietzig, T., Bartsch, C., Richter, C., Laule, M., Baumann, G., & Stangl, K. (2003). Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist: Attenuation of Endothelin-1–Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-κB. Circulation Research. https://doi.org/10.1161/01.res.0000051884.27117.7e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.